Intuitive Surgical stock gains support as BTIG reiterates buy rating and strong Q2 2026 growth
Published on 09/08/2026 at 17:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical stock (ISIN US46120E6023) is back in the spotlight after a fresh analyst reiteration of a buy rating at a USD 469 price target, coming on the heels of strong Q2 2026 results that featured nearly USD 2.9 billion in revenue and double?digit procedure growth as of July 2026.BTIG
Analyst reiteration underscores confidence in growth
On September 8, 2026, BTIG analyst Ryan Zimmerman reiterated a buy rating on Intuitive Surgical and maintained a target price of USD 469 per share, signaling ongoing confidence in the company’s long?term robotics franchise.BTIG According to a separate summary of this stance, the maintained USD 469 target reflects a consistent valuation framework that has been in place since at least October 3, 2023, when BTIG previously affirmed the same level.GuruFocus
A recent analysis notes that Intuitive Surgical shares around USD 366.70 are trading roughly 41.4% below an estimated intrinsic value of USD 625.48, suggesting the stock is at a sizeable discount relative to that valuation model as of early September 2026.GuruFocus While such model?based metrics are not a guarantee, the combination of a reiterated buy rating and a substantial modeled valuation gap highlights how some market observers view the current price as not fully reflecting Intuitive Surgical’s growth prospects.
Q2 2026 results show broad-based growth
Fundamentally, the latest reported quarter is Q2 2026, when Intuitive Surgical posted revenue of USD 2.89 billion, up 19% year over year, driven by approximately 16% worldwide procedure growth across its da Vinci and Ion robotic systems.Stock Titan Within that figure, da Vinci procedures grew about 15% while Ion procedures expanded around 36%, demonstrating that both the core and newer platforms are contributing meaningfully to volume gains.Stock Titan
GAAP net income attributable to Intuitive Surgical in Q2 2026 reached USD 818 million, translating into diluted earnings per share of USD 2.29, while non?GAAP net income came in at USD 1.00 billion, or USD 2.80 per diluted share.Stock Titan Compared with consensus expectations of USD 2.48 per share and revenue of USD 2.83 billion, the company exceeded forecasts by USD 0.32 in EPS and approximately USD 60 million in revenue, underlining a solid beat on both the top and bottom lines for that quarter.MarketBeat
Earlier in Q1 2026, Intuitive Surgical had already demonstrated momentum, reporting revenue of USD 2.77 billion, up 23% from USD 2.25 billion a year earlier, driven by higher product and service sales across U.S. and international markets.Stock Titan Net income attributable to the company in that quarter increased to USD 821.5 million, with diluted EPS rising to USD 2.28 from USD 1.92, as gross profit expanded to USD 1.83 billion and operating income reached USD 855.3 million.Stock Titan Taken together, the Q1 and Q2 2026 figures show a pattern of sustained double?digit revenue growth and meaningful margin expansion, supporting the positive stance taken by covering analysts.
Guidance and emerging growth engines
Looking ahead to the full year 2026, Intuitive Surgical expects worldwide da Vinci procedure growth of approximately 13.5% to 15.5%, alongside a non?GAAP gross profit margin in the range of 68.0% to 69.0% of revenue, including about a 1 percentage?point impact from tariffs.Stock Titan Non?GAAP operating expense growth is projected at 11% to 13%, with management noting that further tariffs could materially affect results, highlighting an external risk factor investors need to consider.Stock Titan
Within Intuitive Surgical’s portfolio, the Ion platform is increasingly recognized as a second growth engine. In Q2 2026, Ion procedures rose 36% year over year to around 48,000, showing accelerating adoption even as the much larger da Vinci ecosystem continues to dominate the overall procedure base.The Globe and Mail An analysis points out that despite strong operational metrics, Intuitive Surgical shares had lost about 35.3% year?to?date compared with an 8.6% decline for its broader medical technology industry cohort, underscoring how valuation and competitive concerns have weighed on the stock in 2026.The Globe and Mail
Valuation, competition and analyst expectations
From a valuation perspective, one recent report cites Intuitive Surgical trading at a forward price?to?earnings multiple of roughly 31.71 times, above the industry average, and carrying a Zacks Rank 3 (Hold) rating.The Globe and Mail At the same time, the Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies growth of about 20.3% versus the prior year, suggesting that analysts expect earnings to continue rising strongly despite the elevated multiple and competitive backdrop.The Globe and Mail
Another earnings?focused summary forecasts that Intuitive Surgical will deliver approximately USD 8.87 in earnings per share for the current fiscal year 2026, building on the robust Q2 2026 EPS of USD 2.80 and confirming that double?digit annual earnings growth remains the base case among covering analysts.MarketBeat For investors, this juxtaposition of strong expected earnings growth and a premium valuation typically means that the execution on procedure expansion, installed base growth and margin discipline will remain central to how the market prices Intuitive Surgical stock going forward.
Robotic systems and da Vinci platform
A key pillar of Intuitive Surgical’s business is its da Vinci robotic surgery system, which has become one of the most widely used platforms for minimally invasive procedures in areas such as urology, gynecology and general surgery. The company’s Q1 and Q2 2026 results show that da Vinci procedure volumes continue to grow at mid?teens rates, driving recurring revenue from instruments, accessories and services alongside system placements.Stock TitanStock Titan
The Ion platform, focused on endoluminal procedures such as lung biopsy, complements da Vinci by opening a different category of robotic?assisted interventions. With Ion procedures up 36% year over year to about 48,000 in Q2 2026, the platform is increasingly contributing to Intuitive Surgical’s overall procedure growth and is positioned as a second engine that could diversify revenue over time.The Globe and Mail Together, these systems underpin the guidance for low? to mid?teens global procedure growth in 2026 and frame how Intuitive Surgical aims to sustain its leadership in robotic?assisted surgery.
Stock price and trading venue
Intuitive Surgical stock is listed on Nasdaq in the United States under the ticker ISRG, with the primary reference price quoted in U.S. dollars on that exchange.MarketBeat As of early September 2026, market data providers show the shares trading in the mid?USD 360 range, notably below both the reiterated USD 469 target from BTIG and the USD 625.48 intrinsic value estimate cited by GuruFocus, illustrating the gap between current market pricing and some valuation benchmarks.GuruFocus
For investors, the key question is whether continued double?digit revenue and earnings growth, underpinned by da Vinci and Ion procedure expansion and supported by a high gross margin profile, will be enough to close that gap over time. The reiterated buy rating, strong Q2 2026 beat versus consensus and a robust full?year 2026 guidance band all provide quantitative support for a constructive view, while tariff risks, intensifying competition in robotic surgery and the stock’s premium valuation multiple remain the main counter?arguments.
Representative product focus: da Vinci system
Among Intuitive Surgical’s offerings, the da Vinci surgical system is the best?known product and a major revenue driver, with worldwide procedures growing about 15% in Q2 2026 and continuing to expand at double?digit rates across multiple surgical specialties.Stock Titan This recurring procedure activity feeds a high?margin stream of instruments and accessories sales, as well as service revenue, which collectively form a large portion of Intuitive Surgical’s business and help support its non?GAAP gross margin guidance of 68.0% to 69.0% of revenue for 2026.Stock Titan
Stock overview and investor takeaway
In summary, Intuitive Surgical stock as of early September 2026 combines strong recent financial performance, with Q2 2026 revenue up 19% to USD 2.89 billion and non?GAAP EPS of USD 2.80 versus a USD 2.48 consensus, with a supportive analyst backdrop that includes a reiterated buy rating and a USD 469 price target from BTIG and a consensus projection of USD 8.87 EPS for the year.MarketBeat At the same time, valuation metrics such as a forward P/E around 31.71 times and concerns over rising competition and tariff exposure explain why the shares have lagged broader industry performance in 2026 even as operational metrics remain compelling.The Globe and Mail For investors following Intuitive Surgical, the next key milestones will likely be the upcoming quarterly earnings releases and any updates to procedure growth guidance or regulatory developments that could reshape the competitive landscape.
Intuitive Surgical stock key data
- Company: Intuitive Surgical, Inc.
- ISIN: US46120E6023
- Ticker: ISRG
- Trading venue: Nasdaq
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
